For U.S. Healthcare Professionals Only
+|Aa|-
Renvela

Renvela®: a noncalcium, nonmetal phosphate binder that is not absorbed and does not accumulate1

Sevelamer in the GI tract

1

Phosphorus binds to sevelamer.

2

Phosphorus, sevelamer, and bile acid travel through the GI tract.

3

Phosphorus and sevelamer are passed out of the body.

4

Sevelamer is not absorbed into the blood.

Sevelamer in the GI tract Sevelamer in the GI tract

Indication

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients.

Please see additional Important Safety Information.

Please see full Prescribing Information for Renvela® or full Prescribing Information for Renagel®

If Renvela® is not available on your state Medicaid program, the patient can likely access Renagel® (sevelamer hydrochloride).

Learn more at Renassist.com.

Indication

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

  • Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renagel or Renvela tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.

Please see full Prescribing Information for Renvela® or full Prescribing Information for Renagel®.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Reference:

  1. Renvela [package insert]. Cambridge, MA: Genzyme Corp.

Important Safety Information

Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients. Click here to read more.